

(19)



(11)

EP 2 440 200 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

A61K 31/195 ^(2006.01) **A61K 31/19** ^(2006.01)
A61K 31/192 ^(2006.01) **A61P 9/12** ^(2006.01)
A61P 1/16 ^(2006.01)

(48) Corrigendum issued on:

15.10.2014 Bulletin 2014/42

(86) International application number:

PCT/US2010/037838

(45) Date of publication and mention of the grant of the patent:

27.08.2014 Bulletin 2014/35

(87) International publication number:

WO 2010/144498 (16.12.2010 Gazette 2010/50)

(21) Application number: **10786721.0**

(22) Date of filing: **08.06.2010**

(54) TREATMENT OF PORTAL HYPERTENSION USING L-ORNITHINE PHENYLACETATE

BEHANDLUNG VON PFORTADERHOCHDRUCK MITTELS L-ORNITHIN-PHENYLACETAT
 TRAITEMENT DE L'HYPERTENSION PORTALE AU MOYEN DE PHÉNYLACÉTATE DE L-ORNITHINE

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

- **ANDERSON, Keith**
San Diego
CA 92127 (US)

(30) Priority: **08.06.2009 US 185158 P**
19.01.2010 US 296377 P
09.09.2009 US 240748 P

(74) Representative: **Bentham, Andrew et al**
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(43) Date of publication of application:
18.04.2012 Bulletin 2012/16

(56) References cited:
WO-A1-2006/056794

(60) Divisional application:
14175859.9

(73) Proprietors:

- **UCL Business PLC**
London W1T 4TP (GB)
- **Ocera Therapeutics, Inc.**
Palo Alto, CA 94301 (US)

- **WRIGHT G ET AL: "773 REDUCTION IN AMMONIA WITH L-ORNITHINE, PHENYLACETATE (OP) BUT NOT ANTI-TNF PREVENTS LPS INDUCED BRAIN EDEMA IN BILE-DUCT LIGATED CIRRHOTIC RATS", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 50, 1 April 2009 (2009-04-01), page S283, XP026496386, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(09)60775-3 [retrieved on 2009-04-01]**

(72) Inventors:

- **JALAN, Rajiv**
Chislehurst BR7 5EP (GB)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 440 200 B8

- **JALAN ET AL: "L-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 69, no. 5, 1 January 2007 (2007-01-01), pages 1064-1069, XP022254346, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2006.12.061**